Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer, retaining the price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Pfizer’s strong financial performance and strategic positioning. Despite the distractions from ongoing negotiations and legal issues in the pharmaceutical sector, Pfizer’s recent earnings report demonstrated robust results across its core business areas, including Oncology, Specialty Care, and Primary Care. This performance has instilled confidence in the company’s ability to meet its guidance, even amidst the variability in COVID-related revenues.
Seigerman also notes that while there are challenges in Pfizer’s commercial growth, the management has effectively set realistic expectations. The company’s strategic acquisitions, funded by COVID-related profits, have strengthened its pipeline, positioning Pfizer well against its peers in the U.S. BioPharma industry. The potential for top-line growth and margin expansion appears underappreciated by the market, suggesting that the stock is undervalued. This, combined with a conservative approach to COVID expectations, supports the Buy rating as Pfizer could outperform in the upcoming quarters.
Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Novo Nordisk, and Bristol-Myers Squibb. According to TipRanks, Seigerman has an average return of 5.4% and a 48.97% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $27.00 price target.